Profile of drug resistance mutations among HIV-1-infected Tunisian subjects failing antiretroviral therapy

Archives of Virology

Volumn 153, Issue 6, 2008, Pages 1103-1108

  Jlizi, A ^a,b   Ben Ammar El Gaaied, A ^b   Slim, A ^a   Tebourski, F ^b   Ben Mamou, M ^a   Ben Chaabane, T ^c   Letaief Omezzine, A ^d   Chakroun, M ^e   Garbouj, M ^f   Ben Rejeb, S ^a  

^a CHARLES NICOLLE HOSPITAL   (Tunisia)

^b FACULTÉ DES SCIENCES DE TUNIS   (Tunisia)

^c LA RABTA HOSPITAL   (Tunisia)

^d FARHAT HACHED HOSPITAL   (Tunisia)

^e FATTOUMA BOURGUIBA UNIVERSITY HOSPITAL   (Tunisia)

^f Direction des Soins de Sante de Base   (Tunisia)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 44449134674     PISSN: 03048608     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00705-008-0104-z     Document Type: Article

References (42)

1. Wainberg MA, Friedland G (1998) Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 279:1977-1983
2. Mellors JW, Munoz A et al (1997) Plasma viral load and CD4 + lymphocytes as prognostic markers of HIV-1 infection. Ann Int Med 126:946-954
3. MacArthur RD, Chen L, Peng G et al (2004) Efficacy and safety of abacavir plus lamivudine versus didanosine plus stavudine when combined with a protease inhibitor, a nonnucleoside reverse transcriptase inhibitor, or both in HIV-1 positive antiretroviral-naive persons. HIV Clin Trials 5:361-370
4. Palella FJ, Delaney KM, Moorman AC et al (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection HIV outpatient study investigators. N Engl J Med 338:853-860
5. Young B, Johnson S, Bahktiari M et al (1998) Resistance mutations in protease and reverse transcriptase genes of human immunodeficiency virus type 1 isolates from patients with combination antiretroviral therapy failure. J Infect Dis 178:1497-1501
6. Valdez H, Connick E, Smith KY et al (2002) Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. Aids 16:1859-1866
7. Tee KK, Kamarulzaman A, Ng KP (2006) Prevalence and pattern of drug resistance mutations among antiretroviral-treated HIV-1 patients with suboptimal virological response in Malaysia. Med Microbiol Immunol 195:107-112
8. Rousseau MN, Vergne L, Montes B et al (2001) Patterns of resistance mutations to antiretroviral drugs in extensively treated HIV-1-infected patients with failure of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 26:36-43
9. Pialoux G, Raffi F, Brun-Vezinet F et al (1998) A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team. N Engl J Med 339:1269-1276
10. Napravnik S, Edwards D, Stewart P et al (2005) HIV-1 drug resistance evolution among patients on potent combination antiretroviral therapy with detectable viremia. J Acquir Immune Defic Syndr 40:34-40
11. Fatkenheuer G, Theisen A, Rockstroh J et al (1997) Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. Aids 11:F113-116
12. Katzenstein DA, Hammer SM, Hughes MD et al (1996) The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med 335:1091-1098
13. Condra JH, Schleif WA, Blahy OM et al (1995) In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374:569-571
14. Descamps D, Flandre P, Calvez V et al (2000) Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team). JAMA 283:205-211
15. Ben Halima M, Pasquier C, Slim A et al (2001) First molecular characterization of HIV-1 Tunisian strains. J Acquir Immune Defic Syndr 28:94-96
16. Direction des Soins de Santé de Base (DSSB). Ministère de la santé publique (2005) Rapport annuel.
17. Obermeyer CM (2006) HIV in the Middle East. BMJ 333:851-854
18. Ben Mamou M, Slim A, Garbouj M et al (2006) Virological diagnosis and follow-up of HIV infection. State of the art and situation in Tunisia. Tunis Med 84:395-402
19. Zouiten F, Ammari L, Goubantini A et al (2003) Effect of triple antiretroviral therapy on Tunisian AIDS profile: study of 139 cases. Tunis Med 81:956-962
20. Stuyver L, Wyseur A, Rombout A et al (1997) Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrob Agents Chemother 41:284-291
21. Kuritzkes D (2002) Drug resistance. Navigating resistance pathways. AIDS Read 12:395-400, 407
22. Vandamme AM, Van Laethem K, De Clercq E (1999) Managing resistance to anti-HIV drugs: an important consideration for effective disease management. Drugs 57:337-361
23. Hirsch MS, Brun-Vezinet F, D'Aquila RT et al (2000) Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA 283:2417-2426
24. Hirsch MS, Richman DD (2000) The role of genotypic resistance testing in selecting therapy for HIV. JAMA 284:1649-1650
25. Cerqueira DM, Amorim RM, Silva RR et al (2004) Antiretroviral resistance and genetic diversity of human immunodeficiency virus type 1 isolates from the Federal District, Central Brazil. Mem Inst Oswaldo Cruz 99:877-882
26. Costagliola D, Descamps D, Assoumou L, et al. (2007) Prevalence of HIV-1 drug resistance in treated patients: a French nationwide study. J Acquir Immune Defic Syndr 46:12-18
27. Gupta RK, Pillay D (2007) HIV resistance and the developing world. Int J Antimicrob Agents 29:510-517
28. Nkengasong JN, Adje-Toure C, Weidle PJ (2004) HIV antiretroviral drug resistance in Africa. AIDS Rev 6:4-12
29. Chesney MA, Ickovics J, Hecht FM et al. (1999) Adherence: a necessity for successful HIV combination therapy. Aids 13(A):S271-278
30. Bangsberg DR, Charlebois ED, Grant RM et al (2003) High levels of adherence do not prevent accumulation of HIV drug resistance mutations. Aids 17:1925-1932
31. Shafer RW (2002) Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev 15:247-277
32. Shah B, Walshe L, Saple DG et al (2007) Adherence to antiretroviral therapy and virologic suppression among HIV-infected persons receiving care in private clinics in Mumbai, India. Clin Infect Dis 44:1235-1244
33. Moyle GJ (1997) Current knowledge of HIV-1 reverse transcriptase mutations selected during nucleoside analogue therapy: the potential to use resistance data to guide clinical decisions. J Antimicrob Chemother 40:765-777
34. D'Aquila RT, Schapiro JM, Brun-Vezinet F et al (2002) Drug Resistance Mutations in HIV-1. Top HIV Med 10:21-25
35. Condra JH, Holder DJ, Schleif WA et al (1996) Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol 70:8270-8276
36. Servais J, Lambert C, Fontaine E et al (2001) Comparison of DNA sequencing and a line probe assay for detection of human immunodeficiency virus type 1 drug resistance mutations in patients failing highly active antiretroviral therapy. J Clin Microbiol 39:454-459
37. Boden D, Hurley A, Zhang L et al (1999) HIV-1 drug resistance in newly infected individuals. Jama 282:1135-1141
38. Stone DR, Corcoran C, Wurcel A et al (2002) Antiretroviral drug resistance mutations in antiretroviral-naive prisoners. Clin Infect Dis 35:883-886
39. Akinsete O, Hirigoyen D, Cartwright C et al (2004) K103 N mutation in antiretroviral therapy-naive African patients infected with HIV type 1. Clin Infect Dis 39:575-578
40. Soriano V (1999) Prevalence of drug resistance mutations in Spain among both naive and pretreated patients. Antivir Ther 4(3):57-63
41. Ribeiro RM, Bonhoeffer S, Nowak MA (1998) The frequency of resistant mutant virus before antiviral therapy. Aids 12:461-465
42. Kozal MJ, Amico KR, Chiarella J et al (2004) Antiretroviral resistance and high-risk transmission behavior among HIV-positive patients in clinical care. Aids 18:2185-2189